Ho Jung Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ho Jung Choi has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Seak Hee Oh
Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
5 shared publications Kyung Mo Kim
Department of Pediatrics Asan Medical Center Children's Hospital, University of Ulsan College of Medicine Seoul Korea
3 shared publications- Kyung Mo Kim
Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
3 shared publications - Yeong Eun Kim
Department of Pediatrics Severance Children's Hospital, Yonsei University College of Medicine Seoul Korea
3 shared publications Dae Yeon Kim
Division of Pediatric Surgery, Department of Surgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 05505, South Korea
2 shared publications- Eun Joo Lee
Department of Pediatrics Yonsei University College of Medicine Seoul South Korea
2 shared publications
Latest Publications
- Open Access
- 5 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 171
Evaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study
Background/Objectives: Azithromycin is widely recommended as the first-line treatment for pediatric Campylobacter enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with Campylobacter enterocolitis. Methods: Pediatric patients under 19 years of age with a new diagnosis of Campylobacter enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with Campylobacter enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy’s effectiveness against untreated cases. Results: The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, p < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, p < 0.001). No significant difference was observed in the duration of vomiting (p = 0.061). Conclusions: Early initiation of macrolide antibiotics in children with Campylobacter enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric Campylobacter enterocolitis.
- 5 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 171
Open AccessEvaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study
Background/Objectives: Azithromycin is widely recommended as the first-line treatment for pediatric Campylobacter enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with Campylobacter enterocolitis. Methods: Pediatric patients under 19 years of age with a new diagnosis of Campylobacter enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with Campylobacter enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy’s effectiveness against untreated cases. Results: The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, p < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, p < 0.001). No significant difference was observed in the duration of vomiting (p = 0.061). Conclusions: Early initiation of macrolide antibiotics in children with Campylobacter enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric Campylobacter enterocolitis.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (13) , e108
Clinical Outcomes of Children With Autoimmune Hepatitis in Korea: A Nationwide Multicenter Study
Ahn JE, et al. J Korean Med Sci. 2026 Apr;41(13):e108. https://doi.org/10.3346/jkms.2026.41.e108
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (13) , e108
Open AccessClinical Outcomes of Children With Autoimmune Hepatitis in Korea: A Nationwide Multicenter Study
Ahn JE, et al. J Korean Med Sci. 2026 Apr;41(13):e108. https://doi.org/10.3346/jkms.2026.41.e108
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70158
Long‐term trend of cumulative incidence of venous thromboembolism in Korean pediatric inflammatory bowel disease
Background: Research on venous thromboembolism (VTE) in pediatric inflammatory bowel disease (PIBD) is rare in Asia. This study aimed to investigate the epidemiological characteristics of VTE within the Korean PIBD population. Methods: A cohort study was conducted on pediatric patients (<17 years) using South Korea's health claims data from 2005 to 2015. IBD and VTE were identified using ICD‐10 codes. We analyzed incidence rate, cumulative incidence, and risk factors, including very early‐onset (VEO, <6 years) IBD. Results: Among 2456 newly diagnosed PIBD patients (2005–2015), 15 (0.6%) developed VTE. The overall VTE incidence was 11.08 per 10,000 patient‐years, with rates of 76.72 for VEO‐IBD and 9.79 for late‐onset (LO, 6–16 years) PIBD. Cumulative VTE rates at 0, 1, 5, and 10 years were 0.04%, 0.08%, 0.56%, and 1.26%, respectively. Age at onset increased VTE risk, while gender and disease type did not show significant differences. Conclusions: The incidence of VTE in PIBD steadily increased over the 10‐year period, with a higher occurrence in those with VEO‐IBD. This study emphasizes the importance of continuous follow‐up for VTE from the early stages of the disease in pediatric IBD patients, particularly focusing on younger age groups.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70158
Long‐term trend of cumulative incidence of venous thromboembolism in Korean pediatric inflammatory bowel disease
Background: Research on venous thromboembolism (VTE) in pediatric inflammatory bowel disease (PIBD) is rare in Asia. This study aimed to investigate the epidemiological characteristics of VTE within the Korean PIBD population. Methods: A cohort study was conducted on pediatric patients (<17 years) using South Korea's health claims data from 2005 to 2015. IBD and VTE were identified using ICD‐10 codes. We analyzed incidence rate, cumulative incidence, and risk factors, including very early‐onset (VEO, <6 years) IBD. Results: Among 2456 newly diagnosed PIBD patients (2005–2015), 15 (0.6%) developed VTE. The overall VTE incidence was 11.08 per 10,000 patient‐years, with rates of 76.72 for VEO‐IBD and 9.79 for late‐onset (LO, 6–16 years) PIBD. Cumulative VTE rates at 0, 1, 5, and 10 years were 0.04%, 0.08%, 0.56%, and 1.26%, respectively. Age at onset increased VTE risk, while gender and disease type did not show significant differences. Conclusions: The incidence of VTE in PIBD steadily increased over the 10‐year period, with a higher occurrence in those with VEO‐IBD. This study emphasizes the importance of continuous follow‐up for VTE from the early stages of the disease in pediatric IBD patients, particularly focusing on younger age groups.
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15786
Epidemiology of pediatric inflammatory bowel disease categorized by age subgroups in Korea
Background: Pediatric inflammatory bowel disease (PIBD) affects different age groups and its incidence is increasing worldwide. However, there is a lack of research focusing on age subgroups in Asian countries. In this nationwide population‐based study, we investigated the epidemiology of PIBD among different age subgroups in Korea. Methods: We analyzed Korean health administration data from 2005 to 2016. Data were divided by age at diagnosis as follows: group 1, 0–1 years; group 2, 2–5 years; group 3, 6–9 years; group 4, 10–16 years. We analyzed the overall incidence, temporal changes, and regional differences by age subgroups, using Poisson regression analysis. Results: From 2005 to 2016, 2734 inflammatory bowel disease (IBD) cases were diagnosed among patients under 17 years of age. In the overall population, the incidence rate of PIBD over the entire study period was 2.248/10 5 person‐years (PY), significantly increasing from 1.173/10 5 PY in 2005–2007 to 3.267/10 5 PY in 2014–2016. The incidence rates in groups 1 and 2 remained unchanged, whereas those of groups 3 and 4 increased significantly. The same trend was observed when analyzed separately for Crohn's disease (CD) and ulcerative colitis (UC). The incidence rates of CD in groups 3 and 4 showed differences between metropolitan and non‐metropolitan areas, whereas those in groups 1 and 2, and UC of all age subgroups showed no difference. Conclusions: The temporal trend and regional differences of PIBD differed among age subgroups, suggesting that genetic and environmental factors have varying impacts on IBD development across different subgroups.
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15786
Epidemiology of pediatric inflammatory bowel disease categorized by age subgroups in Korea
Background: Pediatric inflammatory bowel disease (PIBD) affects different age groups and its incidence is increasing worldwide. However, there is a lack of research focusing on age subgroups in Asian countries. In this nationwide population‐based study, we investigated the epidemiology of PIBD among different age subgroups in Korea. Methods: We analyzed Korean health administration data from 2005 to 2016. Data were divided by age at diagnosis as follows: group 1, 0–1 years; group 2, 2–5 years; group 3, 6–9 years; group 4, 10–16 years. We analyzed the overall incidence, temporal changes, and regional differences by age subgroups, using Poisson regression analysis. Results: From 2005 to 2016, 2734 inflammatory bowel disease (IBD) cases were diagnosed among patients under 17 years of age. In the overall population, the incidence rate of PIBD over the entire study period was 2.248/10 5 person‐years (PY), significantly increasing from 1.173/10 5 PY in 2005–2007 to 3.267/10 5 PY in 2014–2016. The incidence rates in groups 1 and 2 remained unchanged, whereas those of groups 3 and 4 increased significantly. The same trend was observed when analyzed separately for Crohn's disease (CD) and ulcerative colitis (UC). The incidence rates of CD in groups 3 and 4 showed differences between metropolitan and non‐metropolitan areas, whereas those in groups 1 and 2, and UC of all age subgroups showed no difference. Conclusions: The temporal trend and regional differences of PIBD differed among age subgroups, suggesting that genetic and environmental factors have varying impacts on IBD development across different subgroups.
- Open Access
- 1 January 2024
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 27 (1) , 71-76
Successful Use of Bortezomib for Recurrent Progressive Familial Intrahepatic Cholestasis Type II After Liver Transplantation: A Pediatric Case with a 9-Year Follow-Up
Bak YG, et al. Pediatr Gastroenterol Hepatol Nutr. 2024 Jan;27(1):71-76. https://doi.org/10.5223/pghn.2024.27.1.71
- 1 January 2024
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 27 (1) , 71-76
Open AccessSuccessful Use of Bortezomib for Recurrent Progressive Familial Intrahepatic Cholestasis Type II After Liver Transplantation: A Pediatric Case with a 9-Year Follow-Up
Bak YG, et al. Pediatr Gastroenterol Hepatol Nutr. 2024 Jan;27(1):71-76. https://doi.org/10.5223/pghn.2024.27.1.71
- Open Access
- 21 March 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (11) , 1159-1171
Assessment of pathogens and risk factors associated with bloodstream infection in the year after pediatric liver transplantation
Assessment of pathogens and risk factors associated with bloodstream infection in the year after pediatric liver transplantation
- 21 March 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (11) , 1159-1171
Open AccessAssessment of pathogens and risk factors associated with bloodstream infection in the year after pediatric liver transplantation
Assessment of pathogens and risk factors associated with bloodstream infection in the year after pediatric liver transplantation
- Open Access
- 25 February 2022
- Published by Elsevier in EBioMedicine
- Vol. 77, 103890
Clinical characteristics of neonatal cholestasis in a tertiary hospital and the development of a novel prediction model for mortality
- 25 February 2022
- Published by Elsevier in EBioMedicine
- Vol. 77, 103890
Open AccessClinical characteristics of neonatal cholestasis in a tertiary hospital and the development of a novel prediction model for mortality